Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Study of Second-line Chemotherapy Comparing FOLFIRI + Ivonescimab Versus FOLFIRI + Bevacizumab in Microsatellite Stable (MSS)/ Proficient MisMatch Repair (pMMR) BRAF Wild Type (BRAFwt) Advanced Colorectal Cancer (mCRC) Without Liver Metastases

NCT07359456 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07359456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07359456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Study of Second-line Chemotherapy Comparing FOLFIRI + Ivonescimab Versus FOLFIRI + Bevacizumab in Microsatellite Stable (MSS)/ Proficient MisMatch Repair (pMMR) BRAF Wild Type (BRAFwt) Advanced Colorectal Cancer (mCRC) Without Liver Metastases
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
August 31, 2033
Enrollment
130 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer